The Institute for Life Science Entrepreneurship at Kean University is joining the CARB-X Global Accelerator Network, an international consortium of committed scientists and experts working to develop new antibiotics, vaccines, diagnostics and other products to fight drug-resistant superbugs.
ILSE and CARB-X (Combating Antibiotic Resistant Bacterial Biopharmaceutical Accelerator) signed a three-year agreement under which ILSE will serve as an accelerator, providing drug discovery and diagnostics expertise, business strategy and other support to CARB-X’s growing portfolio of innovative antibacterial development projects.
ILSE is a nonprofit organization located in Union that provides incubator space and accelerator services to life science companies.
CARB-X is a global partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria.
“ILSE’s agreement with CARB-X will bring increased innovation and companies from around the world to New Jersey,” said Thomas Richardson, ILSE president in a statement. “Scientists conducting research are central to combating the worldwide crisis of drug-resistant antibiotics. We at ILSE help them identify the most promising development strategies and provide assistance to reach the next milestone,” Richardson said.
According to ILSE, new antibiotics, rapid diagnostics, vaccines and other products are needed urgently to treat bacteria that are increasingly resistant to existing antibiotics.
According to the World Health Organization, an estimated 700,000 people die each year worldwide from bacterial infections. In the United States, an estimated 23,000 people die each year from drug-resistant bacterial infections, according to the Centers for Disease Control & Prevention.
ILSE is the only accelerator in the mid-Atlantic region and is one of only five U.S. organizations in the Global Accelerator Network.
CARB-X, a nonprofit, public-private global partnership based at the Boston University School of Law, currently funds more than 34 early development projects in six countries, including new classes of antibiotics and other life-saving therapeutics, diagnostics and vaccines.
“The expertise of the highly-experienced drug accelerator team at ILSE will likely be a game changer for companies in the CARB-X portfolio who need a professional hand to efficiently guide them through the complexities of drug development. For many companies, it will likely be the difference between successfully developing a drug candidate or not,” said David Perlin, chief scientific officer for the Hackensack Meridian Health’s Center for Discovery and Innovation and a partner with ILSE on the project.